New Delhi, Feb 20: For the first time in India, couples seeking In Vitro Fertilisation (IVF) treatment can access a globally preferred automated egg-freezing technology aimed at improving pregnancy outcomes and enabling the healthy birth of their child. Hana Health by DSS Imagetech has exclusively partnered with Overture Life, a leading developer of automated IVF technologies, to introduce its pioneering automated vitrification platform — DaVitri — to the Indian market.
Overture Life is the first company to achieve live births from both robotic fertilisation and robotic egg freezing. DaVitri is also the first automated egg-freezing platform to receive regulatory clearance from major authorities in the US, UK, and Europe, enabling fertility clinics to standardise one of the most technically demanding steps in IVF — egg vitrification.
This collaboration brings DaVitri into routine clinical use in India, allowing fertility clinics to standardise egg freezing, expand procedural capacity, and support embryologists amid rapidly growing fertility demand.
Standardising a Critical IVF Step
Egg freezing and warming variability remains a significant contributor to inconsistent IVF outcomes and repeated treatment cycles, often resulting in emotional and financial strain for couples.
DaVitri automates vitrification through a regulated microfluidic system, reducing variability at the critical egg-freezing stage. By standardising vitrification under controlled, data-driven protocols, the platform enhances predictability at the earliest stages of IVF treatment, supporting improved embryo yield and reducing the likelihood of repeated cycles.
Ashim Ghatak, Senior Vice President, IVF Division, Hana Health by DSS Imagetech, said:
“DaVitri addresses a core bottleneck in embryology that has historically limited both scale and reproducibility. For patients, every IVF cycle represents hope, time, and an enormous emotional and financial investment. The tiniest variations during egg freezing can affect everything that follows. By standardising vitrification under controlled, data-driven protocols, automation improves predictability at the earliest stages of treatment.”
Scaling Capacity Without Compromising Quality
DaVitri enables both small clinics and large centralised laboratories to significantly increase the number of procedures processed without increasing staffing requirements. Clinical evaluations have demonstrated measurable improvements in post-thaw embryo development compared to manual methods.
By reducing infrastructure requirements from multi-million-dollar investments to a fraction of that cost, the platform makes advanced cryopreservation services more accessible — including for smaller clinics and satellite centres.
Hans Gangeskar, Chief Executive Officer, Overture Life, said:
“India’s fertility clinics are serving a growing and diverse patient population under intense capacity pressure. DaVitri enables clinics to expand access and scale up while protecting consistency and clinical rigour, without sacrificing the highest standards that families deserve. This collaboration positions DaVitri as a service-supported system for Indian clinics seeking to modernise IVF workflows.”
Dr. Hrishikesh Pai, Medical Director at Bloom IVF and CEO at WAGO, added:
“Automation is the future of IVF procedures, and the microfluidics technology from Overture represents a decisive next step in advancing precision and efficiency in cryopreservation.”